Financial statements Pharmindex Poland
Balance sheet data of PHARMINDEX POLAND
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|---|---|---|---|---|---|---|
Total assets | 2 367 729,15 | 3 313 244,25 | 5 129 347,12 | 7 726 556,80 | 10 149 665,33 | 13 294 672,78 | 18 556 995,17 |
A. Fixed assets | 376 795,50 | 186 648,80 | 137 934,13 | 131 773,51 | 215 630,16 | 179 868,75 | 151 621,25 |
B. Current assets | 1 990 933,65 | 3 126 595,45 | 4 991 412,99 | 7 594 783,29 | 9 934 035,17 | 13 114 804,03 | 18 405 373,92 |
C. Share capital contributions (basic funds) | - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
D. Own shares (stocks) | - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Total liabilities | 2 367 729,15 | 3 313 244,25 | 5 129 347,12 | 7 726 556,80 | 10 149 665,33 | 13 294 672,78 | 18 556 995,17 |
A. Equity | 1 980 913,38 | 2 599 470,54 | 4 510 993,94 | 6 817 056,68 | 9 159 860,26 | 12 229 854,47 | 16 955 301,03 |
B. Liabilities and provisions for liabilities | 386 815,77 | 713 773,71 | 618 353,18 | 909 500,12 | 989 805,07 | 1 064 818,31 | 1 601 694,14 |
I. Long-term liabilities | - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
II. Short-term liabilities | 382 708,04 | 710 534,21 | 614 725,47 | 902 163,38 | 986 639,81 | 1 061 995,80 | 1 599 330,51 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.